SoC Clinical Trials

4 actively recruiting trials across 3 locations

▼ -1 trial since July 2026

Pipeline

Phase 2: 2Phase 1/2: 2

Top Sponsors

Universitaire Ziekenhuizen KU Leuven1
UNC Lineberger Comprehensive Cancer Center1
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.1
BioNTech SE1

Indications

Cancer4
Breast Cancer3
Lung Cancer2
Triple Negative Breast Cancer (TNBC), Early Setting1
Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma1

Other1 trial

LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer

Phase 2

Los Angeles, California1 trial

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

USC Norris Comprehensive Cancer Center

Phase 1/2

Stanford, California1 trial

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Stanford Cancer Institute

Phase 1/2

New Haven, Connecticut1 trial

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Yale Cancer Center Clinical Trials Office

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.